• Net cash outflow from operating activities of $576k
• Quarterly receipts from customers were $540k, up 39% from last quarter
• Entered into binding conditional Share Purchase Agreement with Biortica Agrimed Limited

Bod Science Limited (Subject to a Deed of Company Arrangement) ('Bod' or 'the Company') (ASX: BOD), a cannabis focused distribution company, has provided an update on its activities for the three-month period ended 30 September 2025 (Q1 FY2026). The key financial updates include a net cash outflow from operating activities of $576k, a decrease of $1,434k on Q4 FY2025, driven by the payment of administration and other fees incurred since the start of the administration period. Quarterly receipts from customers were $540k, an increase of $152k (39%) on the last quarter and an increase of $348k (181%) on the previous corresponding period, due to increases in sales volumes of existing SKUs and the introduction of new SKUs. The Company also received $496k in funding from Biortica Agrimed Limited to partially pay for its operating expenses. Operationally, the Company remains in a Deed of Company Arrangement (DOCA) with Biortica Agrimed Limited, with Andrew Barnden appointed as Deed Administrator. The Company has executed a binding conditional Share Purchase Agreement with the Biortica ordinary shareholders to acquire all the fully paid ordinary shares in Biortica, in consideration for the issue of ordinary shares in the Company. The DOCA will be effectuated once the conditions subsequent to the DOCA are satisfied, including the passing of various resolutions by shareholders at an extraordinary general meeting expected to be held in late November 2025.

The extraordinary general meeting of the shareholders of the Company is expected to be convened on or before 30 October 2025, being a date after Biortica complies with the majority of the conditions subsequent, with the meeting to be held in late November 2025. The actual date of the extraordinary general meeting will be advised in a formal Notice of Meeting, which will be issued in due course.